EndoStim, Inc., a medical device company, today announced new data were presented on its new neurostimulation therapy for gastroesophageal reflux disease (GERD) at the 2016 Digestive Disease Week (DDW) meeting in San Diego, California. The four presentations included analyses of: one year results of an international multi-center study of EndoStim therapy for refractory GERD; and interim results from EndoStim’s international patient registry.
http://www.prnewswire.com/news-releases/new-data-on-endostim-therapy-for-the-treatment-of-gastro-esophageal-reflux-disease-gerd-presented-at-digestive-disease-week-2016-300276779.htm
New data on EndoStim therapy for the treatment of gastro-esophageal reflux disease (GERD) presented at Digestive Disease Week® 2016